Skip to main
GRI
GRI logo

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio Inc. is positioned favorably within the biotech sector, focusing on therapies for serious diseases linked to immune system dysregulation, with its lead product candidates showing potential for addressing significant market needs. The current market valuation, while adjusted to $40 based on a net present value analysis, still reflects a substantial upside opportunity compared to the present share price, indicating potential for investor returns. Furthermore, the increasing incidence of idiopathic pulmonary fibrosis (IPF), with over 40,000 new cases diagnosed annually, underscores a growing demand for innovative treatments such as those being developed by GRI Bio.

Bears say

GRI Bio Inc. reported a net loss of $3.9 million, translating to an earnings per share (EPS) of $(7.72), which fell short of both internal estimates and consensus expectations, reflecting underlying financial weaknesses. The company is facing significant risks, including balance sheet and liquidity concerns, the potential failure of product candidates to prove safety and efficacy, and challenges in gaining regulatory approvals and commercialization. Additionally, external factors such as changing investor sentiment toward biotech stocks and macroeconomic fluctuations further contribute to a negative outlook for GRI Bio's stock.

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of Dec 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.